Page 41 - anuario 2024
P. 41

Referencias

                  1  -  Singulair®  5  mg.  Ficha  Técnica  del  medicamento.  Agencia  Española  del
                  Medicamento             y           Productos            Sanitarios.           CIMA:
                  https://cima.aemps.es/cima/dochtml/ft/61979/FT_61979.html. Accedido el 11/04/2024.

                  2 - Mayoral K, Lizano-Barrantes C, Zamora V, et al. Montelukast in paediatric asthma
                  and allergic rhinitis: a systematic review and meta-analysis. Eur Respir Rev. 2023 Oct
                  18;32(170):230124.

                  3  -  Aldea  Perona  A,  García-Sáiz  M,  Sanz  Álvarez  E.  Psychiatric  Disorders  and
                  Montelukast in Children: A Disproportionality Analysis of the VigiBase(®). Drug Saf. 2016
                  Jan;39(1):69-78.

                  4  –  FDA.  FDA  requires  Boxed  Warning  about  serious  mental  health  side  effects  for
                  asthma  and  allergy  drug  montelukast  (Singulair);  advises  restricting  use  for  allergic
                  rhinitis.  FDA  Drug  Safety  Communication.  3-4-2020.  https://www.fda.gov/drugs/drug-
                  safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-
                  effects-asthma-and-allergy-drug.

                  5 - Mou Y, Song Q, Zhao C, Fang H, Ren C, Song X. Meta-analysis of the relationship
                  between montelukast use and neuropsychiatric events in patients with allergic airway
                  disease. Heliyon. 2023 Nov 8;9(11):e21842.

                  6 - Ali MM, O’Brien CE, Cleves MA, et al. Exploring the possible association between
                  montelukast  and  neuropsychiatric  events  among  children  with  asthma:  a  matched
                  nested case–control study. Pharmacoepidemiol Drug Saf 2015; 24: 435–445.

                  7 - Glockler-Lauf SD, Finkelstein Y, Zhu J, et al. Montelukast and neuropsychiatric events
                  in children with asthma: a nested case-control study. J Pediatr 2019; 209: 176–182.

                  8  -  Benard  B,  Bastien  V,  Vinet  B,  et  al.  Neuropsychiatric  adverse  drug  reactions  in
                  children initiated on montelukast in real-life practice. Eur Respir J 2017; 50: 17001148.

                  9 - Yilmaz Bayer O, Turktas I, Ertoy Karagol HI, et al. Neuropsychiatric adverse drug
                  reactions induced by montelukast impair the quality of life in children with asthma.  J
                  Asthma. 2022 Mar;59(3):580-589.

                  10  -  Lo  CWH,  Pathadka  S,  Qin  SX,  et  al.  Neuropsychiatric  events  associated  with
                  montelukast in patients with asthma: a systematic review. Eur Respir Rev. 2023 Sep
                  27;32(169):230079



















                                                           41
   36   37   38   39   40   41   42   43   44   45   46